- Home
- TNGX vs GPRE Comparison
TNGX vs GPRE Comparison
Compare TNGX & GPRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TNGX
- GPRE
- Stock Information
- Founded
- TNGX 2014
- GPRE 2004
- Country
- TNGX United States
- GPRE United States
- Employees
- TNGX N/A
- GPRE N/A
- Industry
- TNGX Biotechnology: Pharmaceutical Preparations
- GPRE Major Chemicals
- Sector
- TNGX Health Care
- GPRE Industrials
- Exchange
- TNGX Nasdaq
- GPRE Nasdaq
- Market Cap
- TNGX 248.2M
- GPRE 289.7M
- IPO Year
- TNGX N/A
- GPRE N/A
- Fundamental
- Price
- TNGX $2.49
- GPRE $4.17
- Analyst Decision
- TNGX Strong Buy
- GPRE Buy
- Analyst Count
- TNGX 6
- GPRE 7
- Target Price
- TNGX $12.20
- GPRE $10.42
- AVG Volume (30 Days)
- TNGX 3.5M
- GPRE 1.7M
- Earning Date
- TNGX 05-12-2025
- GPRE 05-08-2025
- Dividend Yield
- TNGX N/A
- GPRE N/A
- EPS Growth
- TNGX N/A
- GPRE N/A
- EPS
- TNGX N/A
- GPRE N/A
- Revenue
- TNGX $40,990,000.00
- GPRE $2,463,097,000.00
- Revenue This Year
- TNGX N/A
- GPRE $3.67
- Revenue Next Year
- TNGX N/A
- GPRE $2.86
- P/E Ratio
- TNGX N/A
- GPRE N/A
- Revenue Growth
- TNGX 10.09
- GPRE N/A
- 52 Week Low
- TNGX $1.03
- GPRE $3.14
- 52 Week High
- TNGX $12.02
- GPRE $18.14
- Technical
- Relative Strength Index (RSI)
- TNGX 62.72
- GPRE 43.10
- Support Level
- TNGX $1.93
- GPRE $4.17
- Resistance Level
- TNGX $2.67
- GPRE $4.42
- Average True Range (ATR)
- TNGX 0.39
- GPRE 0.31
- MACD
- TNGX 0.07
- GPRE -0.06
- Stochastic Oscillator
- TNGX 55.38
- GPRE 0.00
About TNGX Tango Therapeutics Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.
About GPRE Green Plains Inc.
Green Plains Inc manufactures and sells ethanol and ethanol byproducts in two segments based on function. The ethanol production segment, which generates the majority of revenue, includes the production of ethanol, distillers grains, Ultra-High Protein and renewable corn oil. The agribusiness and energy services segment includes grain handling and storage, commodity marketing and merchant trading for company-produced and third-party ethanol, distillers grains, Ultra-High Protein, renewable corn oil, natural gas and other commodities.